Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval from the U.S.

Viatris (NASDAQ:VTRS) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic ...

Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales fell by ...

Venofer was approved in the U.S. in 2000. It was developed by Vifor Pharma, which is now part of CSL Ltd. American Regent, a unit of Daiichi Sankyo, manufactures and sells it in the U.S. under a ...

Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here’s what investors ...

Q2 2025 Earnings Call Transcript August 7, 2025 Viatris Inc. beats earnings expectations. Reported EPS is $0.62, expectations ...

Investing.com -- Viatris Inc (NASDAQ: VTRS) stock rose 2.6% following the U.S. Food and Drug Administration’s approval of the company’s Iron Sucrose Injection, USP, the first generic version of ...

Among Indian generics makers, Iron Sucrose had been considered a key pipeline product for Dr. Reddy’s Laboratories and ...

Viatris demonstrated its commitment to shareholder value by returning over $630 million to shareholders, including $350 million in share repurchases this year. This move highlights the company’s focus ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and weak R&D. Read more on why I rate VTRS a Hold.

Viatris (VTRS) is set to announce Q2 earnings amid EPS and revenue declines. Learn about its recent trials, stock dip, and Wall Street's Hold rating.

Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.